Studies have shown that active fund managers routinely underperform the S&P500 index*​

Allogene Therapeutics, Inc. (NASDAQ: ALLO)

ALLO Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
BUY
Analyst Forecast (1yr):
359.80%

ALLO Stock Analysis

ALLO PE Ratio:

ALLO PEG Ratio: Not Available

ALLO Forward EPS Growth (12 month): 0.00%

ALLO PS Ratio:

ALLO PSG Ratio:

ALLO Forward Revenue Growth (12 month): 400.00%

ALLO Articles

No data was found